Declining Use of CBD Exploration in Choledocholithiasis Declining Use of CBD Exploration in Choledocholithiasis
Over the past 15 years, the use of open and laparoscopic common bile duct exploration in patients with choledocholithiasis has declined markedly, according to data from the National Inpatient Sample (NIS).Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 6, 2016 Category: Surgery Tags: General Surgery News Source Type: news
The Incredible Brain Of Simone Biles
Team USA gymnast Simone Biles twists and flips through air with a seemingly gravity-defying buoyancy. With great precision, she lands on the balance beam as if the 4-inch-wide ledge is an extension of her own body.
As the 19-year-old gymnast competes in the Olympics in Rio de Janeiro this week, pulling out the types of combinations that have been repeatedly called “impossible,” you may ask what it is exactly that sets her apart — is it only practice? Or does Biles have a particular brain wiring that’s given her a repertoire of movements far beyond a human’s humble ability to walk str...
Source: Science - The Huffington Post - August 7, 2016 Category: Science Source Type: news
GLP-1 Analogues: Risk of Gallbladder Disease, Not Pancreatitis GLP-1 Analogues: Risk of Gallbladder Disease, Not Pancreatitis
Taking glucagon-like peptide 1 (GLP-1) analogues is associated with an increased risk of bile duct and gallbladder disease, but not pancreatitis, in people with type 2 diabetes, according to two new studies.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 3, 2016 Category: Surgery Tags: Diabetes & Endocrinology News Source Type: news
Newer Diabetes Drugs Could Boost Risk for Gallbladder and Bile Duct Disease (FREE)
By Kelly Young
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
Use of glucagon-like peptide 1 (GLP-1) receptor agonists is associated with increased risk for gallbladder and bile duct … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 1, 2016 Category: Primary Care Source Type: news
Two incretin-based drugs linked to increased bile duct disease but not pancreatitis
At least two incretin-based drugs – glucagon-like peptide 1 agonists and dipeptidyl peptidase 4 inhibitors – do not appear to increase the risk of acute pancreatitis in individuals with diabetes but... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - August 1, 2016 Category: Endocrinology Source Type: news
